TB-Related Articles

Return to Main Menu

2023 DTBE Publications

Adams T, Miller K, Law M, Pitcher E, Chinpar B, White K, Deutsch-Feldman M, Li R, Filardo TD, Romieu-Hernandez AC, Schwartz NG, Haddad MB, Glowicz J. Systematic contact investigation: an essential infection prevention skill to prevent tuberculosis transmission in healthcare settings. Am J Infect Control. 2023 Jun 22:S0196-6553(23)00478-9. doi: 10.1016/j.ajic.2023.06.014. Epub ahead of print. PMID: 37355098.

Adekoya N, Chang MH, Wortham J, Truman BI. Disparities in Rates of Death From HIV or Tuberculosis Before Age 65 Years, by Race, Ethnicity, and Sex, United States, 2011-2020. Public Health Rep. 2023 Dec 18:333549231213328. doi: 10.1177/00333549231213328. Epub ahead of print. PMID: 38111105.

Baker JJ, Nahar R, Petroelje BK, Goswami ND, Lardizabal AA. Fluoroquinolone-resistant latent tuberculosis infection: A literature review and case series of 5 patients treated with linezolid monotherapy. J Clin Tuberc Other Mycobact Dis. 2023 May 18;32:100376. doi: 10.1016/j.jctube.2023.100376. PMID: 37252368; PMCID: PMC10209533.

Caruso E, Mangan JM, Maiuri A, Bouwkamp B, DeLuca N. Tuberculosis Testing and Latent Tuberculosis Infection Treatment Practices Among Health Care Providers – United States, 2020-2022. MMWR Morb Mortal Wkly Rep. 2023 Nov 3;72(44):1183-1189. doi: 10.15585/mmwr.mm7244a2. PMID: 37917562; PMCID: PMC10629750.

Chorba T. Ars longa, vita brevis. Emerg Infect Dis. 2023 Mar;29(3):674-675. https://dx.doi.org/10.3201/eid2903.ac2903.

Feng PI, Horne DJ, Wortham JM, Katz DJ; CDC Tuberculosis Epidemiologic Studies Consortium. Trends in tuberculosis clinicians’ adoption of short-course regimens for latent tuberculosis infection. J Clin Tuberc Other Mycobact Dis. 2023 Jun 13;33:100382. doi: 10.1016/j.jctube.2023.100382. PMID: 37416302; PMCID: PMC10320582.

Frazier C, Nabity SA, Flood J. Incidence of TB disease among persons who use drugs in California. Int J Tuberc Lung Dis. 2023 Oct 1;27(10):781-783. doi: 10.5588/ijtld.23.0228. PMID: 37749841; PMCID: PMC10519387.

Groenweghe E, Swensson L, Winans KD, Griffin P, Haddad MB, Brostrom RJ, Tuckey D, Lam CK, Armitige LY, Seaworth BJ, Corriveau EA. Outbreak of Multidrug-Resistant Tuberculosis – Kansas, 2021-2022. MMWR Morb Mortal Wkly Rep. 2023 Sep 1;72(35):957-960. doi: 10.15585/mmwr.mm7235a4. PMID: 37651293.

Haley CA, Schechter MC, Ashkin D, Peloquin CA, Cegielski JP, Andrino BB, Burgos M, Caloia LA, Chen L, Colon-Semidey A, DeSilva MB, Dhanireddy S, Dorman SE, Dworkin FF, Hammond-Epstein H, Easton AV, Gaensbauer JT, Ghassemieh B, Gomez ME, Horne D, Jasuja S, Jones BA, Kaplan LJ, Khan AE, Kracen E, Labuda S, Landers KM, Lardizabal AA, Lasley MT, Letzer DM, Lopes VK, Lubelchek RJ, Macias CP, Mihalyov A, Misch EA, Murray JA, Narita M, Nilsen DM, Ninneman MJ, Ogawa L, Oladele A, Overman M, Ray SM, Ritger KA, Rowlinson MC, Sabuwala N, Schiller TM, Schwartz LE, Spitters C, Thomson DB, Tresgallo RR, Valois P, Goswami ND; BPaL Implementation Group. Implementation of BPaL in the United States: Experience using a novel all-oral treatment regimen for treatment of rifampin-resistant or rifampin-intolerant TB disease. Clin Infect Dis. 2023 May 30:ciad312. doi: 10.1093/cid/ciad312. Epub ahead of print. PMID: 37249079.

Kurbatova EV, Phillips PP, Dorman SE, Sizemore EE, Bryant KE, Purfield AE, Ricaldi J, Brown NE, Johnson JL, Wallis CL, Akol JP, Ocheretina O, Van Hung N, Mayanja-Kizza H, Lourens M, Dawson R, Nhung NV, Pierre S, Musodza Y, Shenje J, Badal-Faesen S, Vilbrun SC, Waja Z, Peddareddy L, Scott NA, Yuan Y, Vernon A, Goldberg SV, Swindells S, Chaisson RE, Nahid P; AIDS Clinical Trials Group and the Tuberculosis Trials Consortium. A Standardized Approach for Collection of Objective Data to Support Outcome Determination for Late-Phase TB Trials. Am J Respir Crit Care Med. 2023 Feb 15. doi: 10.1164/rccm.202206-1118OC. Epub ahead of print. PMID: 36790881.

Labuda SM, Seaworth B, Dasgupta S, Goswami ND; BPaL Accelerated Monitoring Project Team. Bedaquiline, pretomanid, and linezolid with or without moxifloxacin for tuberculosis. Lancet Respir Med. 2023 Nov 30:S2213-2600(23)00426-5. doi: 10.1016/S2213-2600(23)00426-5. Epub ahead of print. PMID: 38043563.

Li R, Deutsch-Feldman M, Adams T, Law M, Biak C, Pitcher E, Drees M, Hernandez-Romieu AC, Filardo TD, Cropper T, Martinez A, Wilson WW, Althomsons SP, Morris SB, Wortham JM, Benowitz I, Schwartz NG, White K, Haddad MB, Glowicz JB; Bone Allograft Tuberculosis Investigators. Transmission of Mycobacterium tuberculosis to healthcare personnel resulting from contaminated bone graft material, United States, June 2021- August 2022. Clin Infect Dis. 2023 Jan 20:ciad029. doi: 10.1093/cid/ciad029. Epub ahead of print. PMID: 36660866.

Mangan JM, Burzynski J, deCastro BR, Salerno MM, Lam CK, Macaraig M, Reaves M, Kiskadden-Bechtel S, Bowers S, Sathi C, Dias MP, Goswami ND, Vernon A. Challenges associated with electronic and in-person directly observed therapy during a randomized trial. Int J Tuberc Lung Dis. 2023 Apr 1;27(4):298-307. doi: 10.5588/ijtld.22.0583. PMID: 37035970.

Mangan JM, Woodruff RS, Winston CA, Nabity SA, Haddad MB, Dixon MG, Parvez FM, Sera-Josef C, Salmon-Trejo LAT, Lam CK. Recommendations for Use of Video Directly Observed Therapy During Tuberculosis Treatment – United States, 2023. MMWR Morb Mortal Wkly Rep. 2023 Mar 24;72(12):313-316. doi: 10.15585/mmwr.mm7212a4. PMID: 36952279; PMCID: PMC10042619.

Marks SM, Self JL, Venkatappa T, Wolff MB, Hopkins PB, Augustine RJ, Khan A, Schwartz NG, Schmit KM, Morris SB. Diagnosis, Treatment, and Prevention of Tuberculosis Among People Experiencing Homelessness in the United States: Current Recommendations. Public Health Rep. 2023 Jan 26:333549221148173. doi: 10.1177/00333549221148173. Epub ahead of print. PMID: 36703605.

Marshall KE, Free RJ, Filardo TD, Schwartz NG, Hernandez-Romieu AC, Thacker TC, Lehman KA, Annambhotla P, Dupree PB, Glowicz JB, Scarpita AM, Brubaker SA, Czaja CA, Basavaraju SV. Incomplete tissue product tracing during an investigation of a tissue-derived tuberculosis outbreak. Am J Transplant. 2023 Sep 15:S1600-6135(23)00693-7. doi: 10.1016/j.ajt.2023.09.005. Epub ahead of print. PMID: 37717630.

Miele K, Rock RB, LaCourse SM, Ashkin D, Armitige LY, Pomputius W, Goswami ND. Notes from the Field: Undiagnosed Tuberculosis During Pregnancy Resulting in a Neonatal Death – United States, 2021. MMWR Morb Mortal Wkly Rep. 2023 Dec 8;72(49):1331-1332. doi: 10.15585/mmwr.mm7249a4. PMID: 38060433; PMCID: PMC10715820.

Nabity SA, Marks SM, Goswami ND, Smith SR, Timme E, Price SF, Gross L, Self JL, Toren KG, Narita M, Wegener DH, Wang SH; National Tuberculosis Controllers Association/CDC TB-COVID-19 Collaboration1. Characteristics of and Deaths among 333 Persons with Tuberculosis and COVID-19 in Cross-Sectional Sample from 25 Jurisdictions, United States. Emerg Infect Dis. 2023 Oct;29(10):2016-2023. doi: 10.3201/eid2910.230286. Epub 2023 Aug 30. PMID: 37647628; PMCID: PMC10521611.

Sadowski C, Belknap R, Holland DP, Moro RN, Chen MP, Wright A, Millet JP, Caylà JA, Scott NA, Borisov A, Gandhi NR. Symptoms and Systemic Drug Reactions in Persons Receiving Weekly Rifapentine Plus Isoniazid (3HP) Treatment for Latent Tuberculosis Infection. Clin Infect Dis. 2023 Jun 16;76(12):2090-2097. doi: 10.1093/cid/ciad083. PMID: 36815322; PMCID: PMC10273365.

Salerno MM, Burzynski J, Mangan JM, Hill A, deCastro BR, Goswami ND, Lam CK, Macaraig M, Schluger NW, Vernon AA. Adverse events among persons with TB using in-person vs. electronic directly observed therapy. Int J Tuberc Lung Dis. 2023 Aug 1;27(11):833-840. doi: 10.5588/ijtld.22.0594. PMID: 37880884.

Schildknecht KR, Pratt RH, Feng PI, Price SF, Self JL. Tuberculosis – United States, 2022. MMWR Morb Mortal Wkly Rep. 2023 Mar 24;72(12):297-303. doi: 10.15585/mmwr.mm7212a1. PMID: 36952282; PMCID: PMC10042618.

Scott NA, Sadowski C, Vernon A, Arevalo B, Beer K, Borisov A, Cayla JA, Chen M, Feng PJ, Moro RN, Holland DP, Martinson N, Millet JP, Miro JM, Belknap R. Using a medication event monitoring system to evaluate self-report and pill count for determining treatment completion with self-administered, once-weekly isoniazid and rifapentine. Contemp Clin Trials. 2023 Jun;129:107173. doi: 10.1016/j.cct.2023.107173. Epub 2023 Mar 31. PMID: 37004811.

Stalter RM, Pecha M, Dov L, Miller D, Ghazal Z, Wortham J, Althomsons S, Deutsch-Feldman M, Stewart R, Felix D, Hsu S, Strick LB. Tuberculosis Outbreak in a State Prison System – Washington, 2021-2022. MMWR Morb Mortal Wkly Rep. 2023 Mar 24;72(12):309-312. doi: 10.15585/mmwr.mm7212a3. PMID: 36952619; PMCID: PMC10042616.

Swartwood NA, Testa C, Cohen T, Marks SM, Hill AN, Beeler Asay G, Cochran J, Cranston K, Randall LM, Tibbs A, Horsburgh CR Jr, Salomon JA, Menzies NA. Tabby2: a user-friendly web tool for forecasting state-level TB outcomes in the United States. BMC Med. 2023 Aug 30;21(1):331. doi: 10.1186/s12916-023-02785-y. PMID: 37649031.

Venkatappa T, Shen D, Ayala A, Li R, Sorri Y, Punnoose R, Katz D; Tuberculosis Epidemiologic Studies Consortium. Association of Mycobacterium tuberculosis infection test results with risk factors for tuberculosis transmission. J Clin Tuberc Other Mycobact Dis. 2023 Jun 29;33:100386. doi: 10.1016/j.jctube.2023.100386. PMID: 37426113; PMCID: PMC10328964.

Vonnahme LA, Raykin J, Jones M, Oakley J, Puro J, Langer A, Aiona K, Belknap R, Ayers T, Todd J, Winglee K. Using Electronic Health Record Data to Measure the Latent Tuberculosis Infection Care Cascade in Safety-Net Primary Care Clinics. AJPM Focus. 2023 Sep 28;2(4):100148. doi: 10.1016/j.focus.2023.100148. PMID: 37941821; PMCID: PMC10630620.

Winston CA, Marks SM, Carr W. Estimated Costs of 4-Month Pulmonary Tuberculosis Treatment Regimen, United States. Estimated Costs of 4-Month Pulmonary Tuberculosis Treatment Regimen, United States. Emerg Infect Dis. 2023 Oct;29(10):2102-2104. doi: 10.3201/eid2910.230314. PMID: 37735769; PMCID: PMC10521593.

Winters N, Belknap R, Benedetti A, Borisov A, Campbell JR, Chaisson RE, Chan PC, Martinson N, Nahid P, Scott NA, Sizemore E, Sterling TR, Villarino ME, Wang JY, Menzies D. Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine: an individual patient data network meta-analysis. Lancet Respir Med. 2023 Mar 23:S2213-2600(23)00096-6. doi: 10.1016/S2213-2600(23)00096-6. Epub ahead of print. PMID: 36966788.

Winters N, Schnitzer ME, Campbell JR, Ripley S, Winston C, Savic R, Ahmad N, Bisson G, Dheda K, Esmail A, Gegia M, Monedero I, Dalcolmo MP, Rodrigues D, Singla R, Yim JJ, Menzies D. Identifying patients with multidrug-resistant tuberculosis who may benefit from shorter durations of treatment. PLoS One. 2023 Oct 5;18(10):e0292106. doi: 10.1371/journal.pone.0292106. PMID: 37797071.

Zavala S, Winglee K, Ho CS, Pettit AC, Ahmed A, Katz DJ, Belknap RW, Stout JE; Tuberculosis Epidemiologic Studies Consortium. Examining Test Cutoffs to Optimize Diagnosis of Latent Tuberculosis Infection in Non-US-born People. Ann Am Thorac Soc. 2023 May 9. doi: 10.1513/AnnalsATS.202212-1005OC. Epub ahead of print. PMID: 37159954.